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Abstract: Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive
lysosomal storage disease which results in a striking skeletal phenotype, but does not negatively
impact the intellect of the patient. MPS IVA has a phenotypic continuum that ranges from a
severe and rapidly progressing form to a slowly progressive form. The clinical diagnosis is often
made in the preschool years based on abnormal bone findings on physical examination and
dysplasia on radiographic imaging. Supportive care has been the mainstay in caring for patients.
Orthopedic physicians often form the core of the care team due to the early and severe skeletal
abnormalities; however, systemic disease is common and requires aggressive monitoring and
management. Interdisciplinary care teams often consist of medical geneticists, cardiologists,
pulmonary specialists, gastroenterologists, otolaryngologists, audiologists, and ophthalmologists. With the US Food and Drug Administration’s approval of elosulfase alfa, patients >5 years
of age now have access to this medication from the time of diagnosis. The clinical trial with
once weekly intravenous dosing (2.0 mg/kg per week) showed improvement in the 6-minute
walk test. The composite end point analysis to evaluate the combining changes from baseline
in 6-minute walk test, 3-minute stair climb test, and respiratory function showed that at a dose
of 2.0 mg/kg per week, subjects performed better when compared to placebo. This indication
was clinically meaningful in the treatment group. The treatment was generally well tolerated,
and the uncommon infusion reactions responded well to traditional enzyme replacement therapy
infusion reaction management algorithms. Currently, clinical trials are underway to determine
the efficacy and safety in MPS IVA patients <5 years of age.
Keywords: mucopolysaccharidosis type IVA, elosulfase alfa, enzyme replacement therapy,
Morquio syndrome, lysosomal storage disease, keratan sulfate
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Lysosomal storage disorders (LSDs) are a group of over 50 inherited disorders that
affect the function of lysosomes. These organelles are responsible for metabolizing
and recycling several macromolecule cellular components. Thus, dysfunction of these
organelles leads to lysosome damage and often abnormalities of the lysosome anatomy.
LSDs are classified based on the major accumulated substrate, underlying mechanism,
or defective enzyme. Subgroups of each disorder are usually further subdivided based
on their age of symptom onset (reviewed in Hendriksz et al1 and Regier et al2).
The mucopolysaccharidoses are a group of LSDs characterized by the accumulation of glycosaminoglycans, namely mucopolysaccharides. Mucopolysaccharidoses
are classified into seven types (type I, II, III, IV, VI, VII, and IX) based on the accu-
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mulation of storage products and the underlying enzymatic
deficiency. Mucopolysaccharidosis type IVA (MPS IVA) is
an autosomal recessive LSD caused by genetic changes in
the gene GALNS, leading to deficient or ineffective activity
of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase
(GALNS). This rare disease has an incidence of 1 in 71,000
to 1,179,000.3 GALNS hydrolyzes the sulfate located on the
ends of keratan sulfate (KS) and chondroitin-6-sulfate (C6S).
Therefore, deficiency of GALNS leads to accumulation of
KS and C6S.
MPS IVA caused by GALNS is clinically identical to
MPS IVB, which causes the deficiency of β-galacotosidase
(reviewed in Regier and Tifft4). Thus, it is important that
enzymatic and/or genetic testing be performed to determine
the underlying enzymatic defect in MPS IV since enzyme
replacement is available in MPS IVA but not in MPS IVB.

The natural history of MPS IVA
MPS IVA was originally described by orthopedic experts due
to the severity of the skeletal dysplasia; however, as skeletal
management has improved, the natural history of this disorder has expanded to include respiratory, heart, hearing, eye,
dental, and liver involvement. Thus, patients with MPS IV
are followed by multidisciplinary teams to optimize their outcomes, often with orthopedics at the center of the care group.2
At birth, children with MPS IV have no unique identifiers.
However, within the first few years of life, the most severe
patients present with physical examination findings consistent
with bony abnormalities. Kyphoscoliosis, genu valgum, and
pectus carinatum are the most common presenting symptoms.5 The milder forms of MPS IV often present with hip
problems such as pain, stiffness, and Legg-Calve-Perthes
disease in late childhood or adolescence. In both cases, progressive bone and join involvement over time leads to short
stature, pain, and arthritis. The bone progression can become
disfiguring and lead to pain as well as impaired mobility and
ability to perform activities of daily living (ADLs). Often,
patients notice difficulty with hand strength and dexterity due
to bony changes in the hands and lower arms. The more devastating skeletal concern, odontoid hypoplasia with cervical
instability can lead to neurological damage and devastating
neurological outcomes.5 Spinal canal stenosis could occur at
any level. Upper and lower extremities malalignment are universal, but the severity varies. Common skeletal abnormalities include ulnar deviation of the wrist joint, hip dysplasia,
hip dislocation, and genu valgum. Growth abnormalities
are universal findings and usually severe. Height velocity is
normal until 1–2 years old and then falls below normal.1,6
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Extraskeletal manifestations of MPS IVA are similar to
other MPS and include impaired respiratory function, valvular heart disease, obstructive sleep apnea (OSA), hearing
impairment, corneal clouding, dental abnormalities in both
shape and structure, and, less commonly, hepatomegaly.2
The longitudinal, prospective Morquio A clinical assessment program reviewed a decline of endurance tests, 6-minute
walk test (6MWT), and 3-minute stair climb test (3MSCT),
suggesting decreased functional ability over time.7 Both
endurance tests have been used to monitor overall disease
progression in the clinic and in elosulfase alfa clinical trials. The 6MWT assesses the walking distance in 6 minutes,
and the 3MSCT assesses the number of stairs that subjects
can climb within 3 minutes. These functional endurance
tests are used as an indirect assessment of determining the
overall function and integrated responses of multiple systems
working together, including musculoskeletal, neurological,
cardiovascular, and pulmonary systems.
Besides the progression of bone pathology and decline
of endurance, natural history studies have revealed that other
organ systems also show progressive symptoms. Significant
morbidity is observed due to nonskeletal involvement.8 In
a natural history study over 2 years, changes in the forced
vital capacity (FVC) and maximum voluntary ventilation
(MVV) were observed. For patients <14 years, the values
increased, as would be expected for growth; however, the
values decreased in older patients, which raised concerns
about disease progression.7 The compromised respiratory
function and decreased FVC and MVV are related to multiple factors, including progression of bone abnormalities
and airway obstruction.
MPS IVA is a progressive condition and affects multiple
organ systems. Life expectancy is shortened in the severe
form, and general well-being is impaired. Bone abnormalities leading to joint and bone deformities and spinal cord
compression are the major cause of mobility limitation, pain,
and difficulties in ADLs. Several factors affect respiratory
function such as short stature, chest wall abnormalities (pectus and kyphoscoliosis), and chronic OSA.

Current management strategies for
symptoms of MPS IVA
A multidisciplinary approach is the key to management.
Careful management with orthopedic intervention when
necessary is crucial for MPS IV patients.2 In cases of difficult airway secondary to glycosaminoglycans accumulation in both upper and lower airway, odontoid hypoplasia,
impaired respiratory function, and cardiac problems, it is
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crucial that anesthesia care be administered by teams that
understand the needs of the MPS IV population.9 Due to the
severe growth abnormalities, specific growth charts have
been developed to allow for normalization of children’s
growth.10 Abnormalities of the spine and malalignment
of both upper and lower extremities are progressive and
could lead to disability. Patients should be evaluated by
orthopedics and neurosurgery closely, at least annually.
Neurological examination should be performed at least
every 6 months due to the risk of spinal cord compression.
This would likely include radiography of spine and lower
extremities, as well as whole-spine MRI annually and when
clinically indicated.
Pulmonary specialty involvement is essential to manage
respiratory compromise and sleep apnea.2 Close follow-up by
a cardiology team is needed to monitor for and treat valvular
heart disease.6 An audiology team follows and treats hearing
impairment aggressively. Eye examinations and intervention
for corneal clouding is important to optimize visual outcomes
in patients.8 While the hepatomegaly noted in patients is not
acutely dangerous, the liver size can affect other organs due
to the short stature of patients. Finally, dental abnormalities
can lead to pain and cosmetic difficulties if appropriate dental
care is not identified early.8 Use of multidisciplinary clinics
often improves patient satisfaction and quality of life by
reducing the total number of hospital visits and facilitation
of care coordination.
Within the context of the numerous systemic complications, it is crucial that the care delivery team optimize
learning and social environments for families with MPS IV.
Baseline intelligence is normal; thus, optimization of the

environment and neurologic protection to prevent damage
is crucial for outcomes.2
In 2014, the “International guidelines for the management
and treatment of MPS IVA syndrome” was released.1 These
guidelines were a summary of two meetings of international
experts with extensive experience in managing MPS IVA.
As summarized in Table 1, the recommendations include an
extensive baseline evaluation, with reevaluation at intervals
to identify systemic changes early to allow for monitoring
and intervention.
Treatments for MPS IV have been limited to supportive care until recently. For example, adenotonsillectomy
for OSA, hearing aids for sensorineural hearing loss, and
keratoplasty for corneal clouding have been recommended.
Aggressive supportive and symptomatic surgical and nonsurgical interventions for skeletal abnormalities have been
used. While other MPS were shown to have benefited from
hematopoietic stem cell transplantation, the experience
with MPS IV has been limited and benefits have not been
well defined.2

Pharmacology, mode of action,
pharmacokinetics of elosulfase alfa
Enzyme replacement therapy (ERT) has become a standard
of care for many forms of LSDs. The first ERT was approved
for Gaucher disease in 1996. The limitations of ERT are infusion reaction, high cost, and low penetration of the central
nervous system. With more clinical experience, the algorithm
to prevent and manage infusion reactions has improved. The
cost continues to be a major hurdle for treatment and an
important conversation in the treatment of rare diseases. The

Table 1 Monitoring recommendations for mucopolysaccharidosis type IVA (MPS IV) patients
At diagnosis

Every 6 mo

Annually

Every 1–3 yr

Medical history
Physical examination
Growth evaluation
Neurological examination
Eye examination
Hearing test
Pulmonary function
Sleep study
Electrocardiogram

Medical history
Physical examination
Growth evaluation
Neurological examination
Dental evaluation

Eye examination
Hearing test
Pulmonary function
Electrocardiogram
Echocardiogram
Endurance test
Quality of life and pain assessment
Cervical spine imaging

Electrocardiogram
Echocardiogram
Spine MRI
Sleep study

Echocardiogram
Dental evaluation
Endurance test
Quality of life and pain assessment Functional/ADL
assessment
Hip/pelvis imaging
Whole Spine imaging
Spine MRI
Note: Data from Regier et al.2 aMultiple evaluations performed at the time of diagnosis for baseline measurements should be repeated, as clinically indicated.
Abbreviation: mo, months; yr, years; ADL, activities of daily living.
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low penetration of enzymes through the blood–brain barrier,
leading to low central nervous system penetration, limits the
efficacy of all ERTs. For example, ERT for Gaucher disease
shows improvements in systemic symptoms of type I patients;
however, the most severe forms – type II and III – with neurological regression and early death do not show improvement
with peripheral administration of ERT. Thus, the efficacy of
ERT in these cases is limited and does not change the end
outcome – death from neurological complications. Since
MPS IVA does not have effects on the intellect of patients,
it makes it a perfect candidate for ERT, providing beneficial
outcomes. It is important to note that the enzyme treatment
can prevent disease progression to a certain extent but cannot
reverse most of the pathology present from before treatment.
Currently ERT has been approved for four types of MPS:
MPS I (laronidase; Aldurazyme®, Genzyme, Boston, MA,
USA), II (idursulfase; Elaprase®, Shire, Dublin, Republic of
Ireland), IVA (elosulfase alfa; Vimizim®, Biomarin, Novato,
CA, USA), and VI (galsulfase; Naglazyme®, Biomarin).

Elosulfase alfa mechanism of action
ERT is available only as an intravenous infusion formulation.
The mechanism of action is to provide the enzymatic activity
deficient due to MPS IVA.
Elosulfase alfa is a purified human enzyme produced
using recombinant DNA technology (recombinant human
enzyme or rhGALNS) in the Chinese hamster ovary cell
line. The sequence and enzymatic activity of elosulfase alfa
is identical to the human form. Elosulfase alfa is identical
to the natural human enzyme in terms of the amino acid
sequence and N-linked glycosylation.11,12 One of the oligosaccharide chains contains bis-mannose 6 phosphate, which
binds a receptor at the cell surface (cation-independent
mannose-6-phosphate receptor). Elosulfase alfa replaces
the endogenous enzyme GALN and leads to catabolism of
glycosaminoglycans C6S and KS.13,14 The enzyme is active in
low pH environments and therefore has low activity outside
of lysosomes.

Pharmacokinetics and pharmacodynamics
In humans, pharmacokinetics (PKs) and pharmacodynamics
of elsosulfase alfa were studied in Phase I/II (MOR-002),
Phase II (MOR-008), and Phase III (MOR-004) clinical trials. MOR-002 is a completed Phase I/II, multicenter, openlabel, dose escalation study. The primary objectives were
to evaluate the safety, tolerability, and efficacy of weekly
infusion of elosulfase alfa (BMN110). The study enrolled 20
subjects aged 5–18 years with MPS IVA. Subjects received
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elosulfase alfa over a 36-week dose escalation period of 12
weeks each of 0.1, 1.0, and 2.0 mg/kg per week, followed
by 36–48 weeks of additional treatment at 1.0 mg/kg per
week. MOR-004 is a multinational, multicenter, double-blind,
randomized, placebo-controlled, 24-week Phase III study in
patients with Morquio A syndrome. The objective of this
study was to determine two different dose regimens (2.0
mg/kg per week and 2.0 mg/kg every other week [QOW])
infused intravenously compared to placebo for a total of
24 weeks. MOR-008 is the ongoing Phase II, randomized,
double-blind, multicenter, pilot study of BMN110 dose 2.0
and 4.0 mg/kg per week administered for an initial treatment
period of 27 weeks.
MOR-002 revealed that the PK profile of elosulfase alfa
is not linear over the dose range of 0.1–2.0 mg/kg per week.
The mean values for area under the plasma concentration time
curve from time zero to the time of last measurable concentration (AUC0–t) and maximum plasma concentration (Cmax)
increased more than the increase in dose.11 In vitro studies
in human fibroblasts when using 2.0 mg/kg per week yielded
plasma concentration higher than those seen with 1.0 mg/kg
QOW; Cmax 2,023 and 503 ng/mL, respectively. Furthermore,
the plasma concentration of elosulfase alfa at 2.0 mg/kg per
week was sustained above the Kuptake (2.8–4 nM) of the M6PR
for approximately 6 hours, which was around 1 hour longer
than those seen in dose 1.0 mg/kg QOW.11
According to data from MOR-004 for both dosing
regimens – 2.0 mg/kg per week and 2.0 mg/kg QOW – elosulfase alfa was detected in plasma at the first time point
60 minutes after starting infusion and reached maximum
concentration between 120 and 240 minutes.15,16 Plasma
half-life was short in both dosing regimens; at week 0, t1/2
was 7 minutes for both groups; and at week 22, t1/2 was
19 and 36 minutes in QOW and weekly dosing groups,
respectively.11,19 On the other hand, the in vitro study in
human Morquio fibroblast showed a half-life of 5–7 days.11
The results indicated that the enzyme’s half-life in plasma
is shorter than in tissue, consistent with the uptake of the
enzyme from the plasma to the tissue, as seen in other ERT
regimens previously described.
The safety of a high dose (4.0 mg/kg per week) was
studied in Phase II MOR-008. The results were similar to
MOR-004 in that after week 22, the mean t1/2 was less than
an hour, although with high dose at week 23, the mean t1/2s
were 23.2 and 31.1 minutes for 2.0 and 4.0 mg/kg per week
groups, respectively.17
Consistent with the findings from MOR-002, the differences between dosages in the mean AUC0–t and Cmax were
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higher than dose differences demonstrated in MOR-004 and
MOR-008. This finding indicated that PKs of elosulfase alfa
are not linear over this dosing range.11,17,19 The changes over
time were attributed to neutralizing antibodies that occur in all
patients.14,18 The pharmacodynamic outcome was measured
by the decrease of first morning void urine KS. The level
of urine KS is used to determine PKs, but the level does
not correlate with clinical response. Decreases of urine KS
was detected in all treatment groups, consistently across the
cohorts (MOR-002, -004, and -008).11,17,19

Preclinical data
MPS IVA mice were studied to determine the safety, efficacy,
and tolerability of elosulfase alfa. Animals showed marked
reduction of storage in visceral organs, bone marrow, heart
valves, connective tissues, and ligaments after 12 weeks of
treatment.20 Further evaluation was experimented in newborn
MPS IVA mice receiving ERT at birth. The bone pathology
study showed that chondrocytes were vacuolated, but the
column structure was organized. This evidence suggested that
the enzyme entered cartilage before the cartilage cell layer
becomes mature bone, leading to prevention of the disorganization of cartilage structure seen in MPS IV. These results
indicated that early treatment may prevent bone pathology,
the major symptom of MPS IV.21

Clinical trial data
Trial participants were enrolled in a multinational, multicenter, double-blind, randomized, placebo-controlled,
24-week Phase III study (MOR-004). The cohort was divided
into two different dose regimens (2.0 mg/kg per week and
2.0 mg/kg QOW) infused intravenously compared to placebo. This study recruited only subjects with the ability to
ambulate. All subjects had an average 6MWT distance ≥30
and ≤325 m during screening. A total of 176 patients (ages
5–57 years) were enrolled. One patient discontinued due to
withdrawal of consent from the weekly treatment group. The
primary efficacy measure was 6MWT, a measure of endurance. Secondary efficacy outcomes were 3MSCT and urine
KS normalization. Tertiary measures evaluated were pulmonary function (FVC, MVV, and forced expiratory volume
in 1 second). Additional tests and measures were collected,
including anthropometric measures, audiogram to evaluate
hearing, echocardiogram to evaluate cardiac valve function,
corneal clouding and radiographic examination, MPS Health
Assessment Questionnaires to evaluate quality of life, inflammatory markers (tumor necrosis factor α), and bone–cartilage
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metabolism (c-terminal crosslinked C-telopeptide CTX1 and
type IIA collagen N-propeptide PIIANP).11,19
At week 24, elosulfase alfa administered weekly significantly improved the 6MWT distance compared to placebo
(22.5 m; P=0.0174). The 3MSCT was not significantly
changed in both weekly and QOW cohorts compared to
placebo. Rapid and sustained urine KS was found in both
treatment arms. Other tertiary improvements were detected
numerically, including FVC, MVV, standing height, and
growth rate in subjects with expected open growth plates
(males <18 years; females <15 years).15,19 The differences
in audiometry, echocardiogram, corneal clouding, or lower
extremities bone length were small. Inflammatory marker was
not changed in treatment group. Levels of CTX1 and PIIANP
were not increased after treatment (elevation of both markers suggests bone formation). Since the tertiary end points
of the Phase III study were not designed to have sufficient
power, different composite end point analysis methods such
as prespecified composite end point and O’Brien’s rank-sum
composite end point were applied to allow for evaluation
of treatment impact across multiple domains. The analyses
demonstrated that the 2.0 mg/kg per week group had received
benefit of treatment when the combination of changes from
baseline of 6MWT, 3MSCT, and MVV were explored.15
The trial results recommended studies in younger and preor mildly symptomatic patients to determine the maximal
benefit of treatment.15
The findings from ongoing high-dose 4.0 mg/kg per
week versus recommended dose 2.0 mg/kg per week in highfunctioning subjects (≥7 years and able to walk ≥200 m in
6MWT at screening) revealed numerical improvement in
3MSCT, cardiopulmonary exercise test, muscle strength,
and pain in 4.0 mg/kg per week arm.

Treatment administration
The recommended dose is 2.0 mg/kg per week intravenous
infusion over 3.5–4.5 hours, based on infusion volume. The
final volume is 100 mL for patients <25 kg and 250 mL for
patients >25 kg. The ERT is diluted in 0.9% sodium chloride
injection. For patients <25 kg, the infusion rate should be
3 mL/h for the first 15 minutes and increased to 6 mL/h for
the next 15 minutes. If this rate is tolerated, it can be increased
by 6 mL/h every 15 minutes, not to exceed 36 mL/h.
For patients weighing ≥25 kg, initial infusion rate should
be 6 mL/h for 15 minutes, and then the ramping regimen
is begun at 12 mL/h for 15 minutes to a maximal rate of
72 mL/h.
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Premedication with nonsedative antihistamine with or
without antipyretics should be administered 30–60 minutes
before infusion. A nonsedating formulation is preferred due
to the risk of sleep apnea and airway difficulty in a sedating
antihistamine.

Adverse events and reactions
Due to the size of the cohort and the short period of time
in use, it is likely that additional adverse reactions may be
identified as use of this ERT continues. Of the 235 patients
enrolled in the clinical trail, 16 (6.8%) experienced signs and
symptoms consistent with anaphylaxis (cough, erythema,
throat tightness, urticarial, hypotension, dyspnea, gastrointestinal symptoms). The timing of these reactions was as early as
30 minutes after beginning infusion to 3 hours after infusion
was completed. All but two subjects were able to receive
subsequent elosulfase alfa infusion with infusion rate adjustments and/or medical intervention. Hypersensitivity reactions
occurred in 18.7% and were observed from 30 minutes after
start of infusion to as late as 6 days after infusions.11,12 Of
the data from MOR-004, the most common adverse events
were headache (20.3%), pyrexia (18.6%), vomiting (15.3%),
nausea (13.6%), diarrhea (11.9%), fatigue (11.9%), upper
abdominal pain, upper (8.5%), cough (8.5%), oropharyngeal
pain (5.1%), abdominal pain (3.4%), and chills (1.7%).19
Most recently, a small study with children <5 years of
age was completed. The group received 2.0 mg/kg per week
for 52 weeks. Adverse events requiring infusion interruption
and medical intervention occurred in 0.8% of infusions.
Both growth velocity and urine KS levels were improved
on treatment.22

Adverse reactions – prevention and
management
Premedication with a nonsedating antihistamine with or
without an antipyretic reduced the risk of adverse reactions
in Phase I/II clinical trials.19 Premedication with sedating
antihistamine, antipyretic, H2 blockers, leukotriene receptor
antagonists, oral cromolyn sodium (personal communication), and/or steroids should be considered if the patient
has a history of adverse reactions or allergies. Additionally,
decreasing the infusion rate by 25%–50%, especially during the first 1–2 hours, is helpful if the reaction is early in
the infusion course (personal experience). For patients with
airway management or positive pressure during sleep secondary to sleep apnea, an airway patency evaluation should
be performed prior to beginning ERT. Furthermore, oxygen
should be available during the infusion therapy.
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Postponement of ERT infusion should be highly considered in patients with acute infection, fever, or respiratory
illness, due to an increased risk of hypersensitivity reactions.13
For acute hypersensitivity reaction, immediate medical
care should be initiated. For mild-to-moderate reactions,
slowing or stopping infusion should be considered. Additionally, administering antihistamines, antipyretics, and/or
steroids should be considered.
For severe anaphylaxis reactions, infusion should be discontinued and breathing and circulation evaluated. Stabilizing
the airway, giving oxygen supplementation, and administering epinephrine intramuscular injection and/or intravenous
fluids for hypotension should be considered.

Patient evaluation of elosulfase alfa
Clinical trials demonstrated that treatment improved 6MWT
and provided positive and meaningful changes in several
clinical parameters. Preclinical studies indicated that early and
presymptomatic treatment could prevent some progression of
bone pathology. Further studies are necessary to demonstrate
the efficacy of treatment in the relatively healthy population.
Treatment should be initiated as soon as the diagnosis is made.
The results of treatment may be different in each patient due
to the high heterogeneity of the natural history. Expectation
and goals of treatment of each family are different and should
be discussed before starting the treatment. The efficacy of
ERT on bone is not impressive. Patients should continue to
follow closely with orthopedics. Furthermore, growth did
not improve with treatment; however, the age of treatment
initiation has not been clearly elucidated. The one study in
children <5 years of age has shown short-term growth velocity improvement; however, long-term studies have not been
published. Various parameters should be closely monitored
throughout the treatment course with ERT. As with any ERT
requiring weekly infusion, the loss of quality of life due to
the frequent infusions must be offset by the perceived benefit
of the treatment. This logistic issue could be managed but
requires collaboration from other supporting systems and
persons. For example, home infusion therapy could be preferably provided during the weekends or weekday evenings for
the adult patients to avoid their work obligation issue, while
pediatric patients can receive treatment during the weekdays
since arrangement can be made more easily for their education requirement such as homework assignments or homeschooling (especially severe mobility impaired patients).
Patient satisfaction has been fair based on the severity of
the symptoms existing before ERT. For severe groups, the
expectations are improvement of pain, ADLs, and ability to
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ambulate without using equipment. Even small changes such
as ability to walk independently for a few feet could impact
life (personal conversation). For mild-to-moderate symptom
groups, the major expectations are improvement of endurance,
exercise tolerance, and possible prevention of bone deformity
progression. The consistency in receiving infusions was found
to be higher in the home infusion group than those receiving
infusions at an infusion center, due to the travel requirement.

The future of elosulfase alfa
Long-term outcome studies will be crucial to determine the
role of elosulfase alfa on the bone outcomes of patients. Furthermore, based on the natural history outcomes described,
long-term changes in progression of disease will be crucial
to demonstrate the long-term efficacy of ERT treatment in
MPS IVA.7 One measurement of initiation of elosulfase alfa
treatment will be the number of patients that remain in the
untreated arm of the natural history study, either by choice
or due to inaccessibility of the ERT.
Donida et al described a cohort of MPS IVA patients
receiving ERT therapy with elevated interleukin-6 and
decreased glutathione levels, suggesting a proinflammatory
and pro-oxidant state in these patients.23 The study did not
include a cohort of MPS IVA patients not receiving ERT
for comparison. This study supports further investigation of
using antioxidants and antiinflammatory agents in combination with ERT to optimize patient outcomes.
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